TRCT
BLTE

Tower Research Capital (TRC)’s Belite Bio BLTE Stock Holding History

Tower Research Capital (TRC)’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14
Closed -$927 – 5267
2025
Q1 		$927 Buy
+14
New +$843 ﹤0.01% 4799

Other funds holding BLTE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s BLTE Position: Q2 2025 in Review

Tower Research Capital (TRC) sold out of Belite Bio (BLTE) in Q2 2025, closing a stake of 14 shares — an estimated $927 sold.

Tower Research Capital (TRC) first reported a position in BLTE in Q1 2025 and held it in 1 quarter. The position peaked at $927 in Q1 2025. 18 funds tracked by Wall St. Rank hold BLTE as of Q2 2025.

  • Tower Research Capital (TRC) reported no remaining Belite Bio position as of Q2 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 14 Belite Bio shares in Q2 2025, an estimated $927.
  • Tower Research Capital (TRC) first reported a position in Belite Bio in Q1 2025 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s Belite Bio position peaked at $927 in Q1 2025.
  • 18 funds tracked by Wall St. Rank held Belite Bio as of Q2 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.